PHOENIX, Ariz. Jan. 8, 2009 Physician-scientists from the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare will present their latest findings and techniques at a national conference designed to provide cancer doctors with new treatments for their patients.
"Molecular Oncology: The Sixth Vital Sign, What Every Oncologist Should Know" is intended to help cancer doctors provide better diagnosis, early detection as well as drugs and other treatments that in some cases can slow the growth or even shrink tumors.
"Given the explosion of new information on the genetic and cellular features of malignancy, the modern oncologist must master the significance and application of cancer-related sciences,'' said Dr. Ramesh K. Ramanathan, Medical Director of TGen Clinical Research Services at Scottsdale Healthcare, a partnership between TGen and Scottsdale Healthcare Corp.
Beyond the five vital signs of pulse, respiration, temperature, blood pressure and pain, is a new sixth vital sign molecular therapeutics. This is the ability to identify the causes of disease at the molecular level in order to provide the right drugs in the right amounts at the right times for the specific needs of individual patients; what is becoming better known in health circles as personalized medicine.
"This gap in knowledge and its application in clinical practice will be addressed in this conference,'' said Dr. Ramanathan, a Senior Investigator at TGen.
Dr. Ramanathan is the co-program director of the conference, along with Dr. Daniel Von Hoff, TGen's Physician-In-Chief and the Chief Scientific Officer at TCRS. Both doctors conduct groundbreaking personalized-medicine research and clinical drug trials at TCRS in Scottsdale, and both are on the clinical faculty of the University of Arizona College of Medicine. Both will present at the conference.
Other TGen and Scottsdale Healthcare scientists scheduled to present include: Dr. Jeffrey Trent, TGen's President and Scientific Director; Dr. Raoul Tibes, Director of the Hematological Malignancies Program at TCRS and an Associate Investigator at TGen; Dr. Stephen P. Anthony, Chief Medical Officer of TGen Drug Development Services (TD2) and a Senior Investigator at TGen; Dr. John Carpten, Director of TGen's Integrated Cancer Genomics Division and a Senior Investigator at TGen; and Gayle Jameson, M.S.N., Director of Supportive Care at TCRS and an Associate Investigator at TGen.
Besides oncologists, the target audience includes all physicians and health professionals involved in caring for cancer patients, and researchers interested in new cancer diagnostics and therapeutics.
Key objectives of the conference include:
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute